BMS, Incyte to evaluate combination regimen of two new immunotherapies for multiple cancers
The evaluation of BMS’ investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, will be done in a Phase I/II trial. Multiple tumor